Endometrial Cancer

P3, N=1156, Suspended, Alliance for Clinical Trials in Oncology | Recruiting --> Suspended

P1, N=57, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting

Both HER2 IHC positive (3+) and FISH positive occur exclusively in pure USC tumors. HER2 gene amplification can be observed in any HER2 IHC levels.

The use of PARP inhibitors and targeted therapies adds complexity to surgical decisions. Ongoing trials and new therapeutic strategies are expected to enhance the management and outcomes of OC.

These data provide an expanded understanding of the molecular underpinnings of EMCG-including the first description of a SMARCA4 frameshift variant in this entity-and demonstrate that while gastrointestinal marker immunoexpression is relatively common among endometrial carcinomas, strictly defined EMCG remains rare (<1%). As awareness of this entity grows, pathologists should take care not to over-interpret gastrointestinal marker expression as stand-alone evidence of an EMCG diagnosis.

MSI testing which has been used historically to identify patients with Lynch Syndrome and evaluate the severity and prognosis of MSI carcinomas now plays an important role in identifying patients who will benefit from targetable therapy. MMR study therefore recommended in all cases of endometrial carcinomas and detection of MMR proteins by IHC can indirectly reflect the status of MSI and is a reliable method of MSI detection.

DZD demonstrated a potentially beneficial effect by improving uterine anti-oxidant capacity and preventing atrophy, but without the hyperplastic changes associated with estradiol. These findings suggest that DZD may be a safer alternative for managing hypoestrogenic conditions, warranting further investigation.

Integrating DNA methylation markers into ECT offers a non-invasive and highly accurate approach to EC screening. This model's high diagnostic accuracy and reliability have the potential to transform EC diagnosis, reducing reliance on invasive procedures and improving clinical management.

P1/2, N=260, Completed, Amgen | Active, not recruiting --> Completed

P1, N=28, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

P=N/A, N=0, Withdrawn, City of Hope Medical Center | N=126 --> 0 | Initiation date: Dec 2025 --> Jul 2026 | Not yet recruiting --> Withdrawn